

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Maryland Physicians Care considers Mechanical Circulatory Support (**Ventricular Assist Device**) – Percutaneous and Permanent medically necessary for the following:

Indications for Mechanical Circulatory Support (LVAD)

All criteria are substantiated by the latest evidence-based medical literature. To enhance transparency and reference, Appropriate Use (AUC) scores, when available, are diligently listed alongside the criteria. ⁽¹⁾ (See **AUC Score**)

Overview

Mechanical Circulatory Support (MCS) or Ventricular Assist Devices (VAD) are indicated for management of members presenting with advanced heart failure (see **Definitions**) refractory to the administration of maximally tolerated Guideline Directed Medical Therapy (GDMT) when heart transplantation is not immediately available. The approach to MCS is dependent on the clinical scenario. MCS may be used as a bridge to recovery, when return of satisfactory ventricular function is anticipated; as bridge to transplantation in critically ill members listed for heart transplantation (OHT); and as destination therapy when the member is not a candidate for transplantation. These designations are not rigid and may change as the member's clinical course evolves.

Bridge to Recovery ^(2,3):

Potentially fatal low cardiac output in situations where recovery is possible or probable. Clinical scenarios for MCS for Bridge to Recovery (**AUC Score 5**) include:

- Acute myocardial infarction complicated by cardiogenic shock ⁽⁴⁾ (**AUC Score 8**)
- Acute myocarditis with shock ⁽⁴⁾ (**AUC Score 8**)
- Acute cardiac failure following cardiac surgery ^(4,5) (**AUC Score 8**)
- MCS using a nondurable (temporary) support device is recommended in members with multiorgan failure, sepsis, or on mechanical ventilation to allow successful optimization of clinical status and neurological assessment before consideration of a long-term device ^(4,5) (**AUC Score 7**)
- Dilated nonischemic cardiomyopathy of recent onset refractory to maximally tolerated GDMT ⁽⁴⁾ (**AUC Score 7**)
- Post-cardiotomy shock with failure to wean from cardiopulmonary bypass ^(4,5) (**AUC Score 9**)

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

- For members with severe renal dysfunction, initial support and nondurable MCS (temporary device) to assess for potential of renal recovery before implanting durable MCS may be undertaken ^(4,5) **(AUC Score 5)**

Bridge-to-Transplantation ⁽²⁾:

- Device must be FDA-approved for bridge to transplant use and used according to labeling instructions **(AUC Score 8)**. These are durable devices, and include extracorporeal MCS, implantable MCS, and total artificial heart (TAH) **AND**
- The member must be approved and listed as a candidate for heart transplantation or be undergoing evaluation of candidacy by an interdisciplinary patient selection committee ⁽⁶⁾ **(AUC Score 8) AND**
- NHYA class IV symptoms despite optimal GDMT or members deemed to be dependent on IV inotropes ⁽⁷⁾ **(AUC Score 8)**

Clinical scenarios for MCS for Bridge to Transplantation MCS include ⁽²⁾:

- Severe reductions in cardiac output or noncardiac co-morbidities such that survival and successful cardiac transplantation are unlikely without mechanical circulatory support ⁽⁶⁾ **(AUC Score 8)**
- Impending cardiogenic shock despite inotropic support and intra-aortic balloon pump (\pm IABP) in presence of acute renal dysfunction (creatinine level > 2.0) that is deemed secondary to insufficient renal blood flow and is unresponsive to inotropic support ⁽⁶⁾ **(AUC Score 8)**
- Pulmonary hypertension (PA systolic pressure > 60) that persists despite optimal medical and inotropic therapy **(AUC Score 8)**
- In members with treatment-refractory recurrent sustained ventricular tachycardia or ventricular fibrillation in the presence of an untreatable arrhythmogenic substrate (e.g., giant cell myocarditis, scar, sarcoidosis), biventricular support or a TAH is preferred over isolated LV support ^(4,6) **(AUC Score 7)**

Destination Therapy (DT) or Long-term Therapy ⁽²⁾:

- Device must be FDA-approved for destination therapy use and used according to labeling instructions **(AUC Score 8)**, **AND**
- Members with a major contraindication to cardiac transplantation **(AUC Score 8)**, **AND**
- Dependence on intravenous inotropic support ⁽³⁾ **(AUC Score 8)**, **OR**
- Class IV heart failure with expected mortality exceeding 50% in one year despite maximum GDMT ⁽³⁾ **(AUC Score 8)**

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

- Indications for Right Ventricular Assist Device Implantation/Utilization. ⁽⁵⁾ Support with an RVAD should be performed in members with medically refractory RV failure after durable LVAD implantation
- Members with high-risk preoperative features for right ventricular failure may undergo planned RVAD implantation before worsening of cardiogenic shock

Contraindications for Ventricular Assist Device

Absolute Contraindications ^(5,7,8)

- Irreversible hepatic disease
- Irreversible renal disease (GFR < 30, not expected to recover)
- Irreversible neurological disease (e.g., severe dementia, major recent stroke)
- Member refusal of medical adherence that is necessary for post-operative recovery
- Severe psychosocial limitations
- Severely restricted pulmonary function
- Neuromuscular or musculoskeletal disease that impairs rehabilitation
- Active systemic infection
- Inability to tolerate anticoagulation
- Active bleeding diathesis
- Prolonged intubation
- Severe, uncorrectable right ventricular failure (for isolated LVAD)
- Small LV cavity size (LVEDD < 4.5 cm for LVAD)
- Severe aortic regurgitation (unless corrected)
- Severe tricuspid/pulmonary valve disease
- Severe technical/surgical barriers (e.g. hostile mediastinum, chest wall deformity)
- Untreated/active malignancy with < 2 years life expectancy
- Severe peripheral vascular disease (PVD)*
- Active substance abuse
- Impaired cognitive function
- Unstable psychiatric conditions
- Lack of social support
- DMCS is relatively contraindicated in the setting of diabetes-related proliferative retinopathy, very poor glycemic control, severe nephropathy, vasculopathy, or peripheral neuropathy
- Active pregnancy ⁽⁵⁾

*NOTE: Durable MCS may be used in selected members with manageable PVD ⁽⁸⁾

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

Relative Contraindications ^(5,8)

- Advanced age (> 80 years old)
- Severe obesity (BMI >35–40) or severe cachexia
- Severe pulmonary disease not amenable to transplant/VAD
- Severe non-cardiac comorbidities

Background

Bridge to Recovery

This category of MCS includes the use of nondurable percutaneous support devices (VADs), which are used for cardiogenic shock when the risk of implantation of a durable device is prohibitive or recovery of function after short-term support is anticipated. These devices are removed once clinical recovery has occurred, or at the time of implantation of durable MCS. Under certain conditions, durable LVADs may be implanted as a bridge to recovery when the recovery period is anticipated to be prolonged.

Nondurable MCS devices include:

- Intra-Aortic Balloon Counter-Pulsation (IABP)
- Extracorporeal Membrane Oxygenation (ECMO)
- Extracorporeal MCS pump (implanted via sternotomy)
- Percutaneous MCS pump

Bridge to Transplantation

Implantation of a durable left ventricular assist device (LVAD) in members who are eligible for cardiac transplantation but in whom a donor heart is not available in the setting of refractory Class IV heart failure requiring inotropic support despite maximally tolerated GDMT.

Destination Therapy

Implantation of a durable left ventricular assist device (LVAD) in members who have refractory Class IV heart failure requiring inotropic support despite maximally tolerated GDMT but are not candidates for heart transplantation.

Right Ventricular Assist Devices (RVADs)

Right heart failure after DLVAD implantation may be managed medically in many cases. RVAD is indicated when hemodynamic indices fail to improve with medical therapy, and before end-organ damage is encountered. Both ECMO and RVAD have been used to support RV recovery after DLVAD implantation. Newer percutaneous RVAD devices

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

provide hemodynamic unloading comparable to surgical devices with less morbidity and may be appropriate for selected members. ⁽⁴⁾

Definitions

Advanced Heart Failure: Consensus for this definition is difficult to achieve but is widely accepted to include: (1) Clinically significant circulatory compromise with class IV symptoms and requiring inotropic support; (2) Frequent hospitalizations for heart failure, resulting in consideration of heart transplantation or resulting in anticipated life expectancy < 2 years; and (3) Interference with activities of daily living. ⁽⁷⁾ Objective measurements may include $VO_2 \leq 14$ ml/kg/min, or 6-min walk distance < 300 m. Members may manifest intolerance to recommended heart failure therapy due to hemodynamic instability.

Clinical manifestations of advanced heart failure include, but are not limited to, the following ⁽⁷⁾:

- Left ventricular ejection fraction (LVEF) $\leq 30\%$
- Inotrope dependence
- Frequent hospitalizations for HF in the past 12 months
- Refractory clinical congestion
- Progressive deterioration in renal or hepatic function
- Worsening right-sided HF or secondary pulmonary hypertension
- Low systolic blood pressure (SBP) ≤ 90 mm Hg
- Cardiac cachexia
- Persistent hyponatremia (serum sodium, < 134 mEq/L)
- Refractory or recurrent ventricular arrhythmias; frequent ICD shocks
- Increased predicted 1-year mortality (eg, > 20%) according to HF survival models (e.g., MAGGIC, SHFM)

AUC Score

A reasonable diagnostic or therapeutic procedure can be defined as that for which the expected clinical benefits outweigh the associated risks, enhancing patient care and health outcomes in a cost-effective manner. ⁽¹⁾

- Appropriate Care- Median Score 7-9
- May be Appropriate Care- Median Score 4-6
- Rarely Appropriate Care- Median Score 1-3
- This Policy first defaults to AUC scores established by published, evidence-based guidance endorsed by professional medical organizations. In the absence

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

of those scores, we adhere to a standardized practice of assigning an AUC score of 6. This score is determined by considering variables that ensure the delivery of patient-centered care in line with current guidelines, with a focus on achieving benefits that outweigh associated risks. This approach aims to maintain a robust foundation for decision-making and underscores our commitment to upholding the highest standards of care.^(1,7,9-12)

Acronyms/Abbreviations

DMCS: Durable Mechanical Circulatory Support
DT: Destination Therapy
ECMO: Extracorporeal Membrane Oxygenation
GDMT: Guideline-Directed Medical Therapy
HF: Heart Failure
IABP: Intra-Aortic Balloon Counter-Pulsation
LVAD: Left Ventricular Assist Device
LVEF: Left Ventricular Ejection Fraction
MAGGIC: Meta-analysis Global Group in Chronic Heart Failure
MCS: Mechanical circulatory support
PVD: Peripheral Vascular Disease
RVAD: Right Ventricular Assist Device
SHFM: Seattle Heart Failure Model
TAH: Total Artificial Heart
VAD: Ventricular Assist Device

Codes

CPT Codes	
Code	Description
33975	Insertion of ventricular assist device; extracorporeal, single ventricle
33976	Insertion of ventricular assist device; extracorporeal, biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
33980	Removal of ventricular assist device, implantable intracorporeal, single ventricle
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
33982	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

33983	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
33991	Insertion of ventricular assist devices, percutaneous including radiological supervision and interpretation; left heart, both arterial and venous access, with transseptal puncture
33995	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only
33997	Removal of percutaneous right heart ventricular assist device, venous cannula, at separate and distinct session from insertion

Policy History

Date	Summary
February 19, 2026	<ul style="list-style-type: none"> This guideline was renumbered from PA.051 Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent Annual Review - Formatting updates throughout; replaced patient with member throughout; updated Indications, Overview, Bridge to Recovery, Bridge to Transplantation, Destination Therapy (DT) or Long-term Therapy, Contraindications for Ventricular Assist Device Sections; added Relative Contraindications section; moved AUC Score section down and updated it; updated Acronym/Abbreviations Section; updated description of procedure code 33991; added Policy History Log; replaced outdated References with updated References

References

- Hendel RC, Lindsay BD, Allen JM, et al. ACC Appropriate Use Criteria Methodology: 2018 Update. *J Am Coll Cardiol*. 2018;71(8):935-948. doi:10.1016/j.jacc.2018.01.007
- Kirklin JK, Naftel DC. Mechanical circulatory support: registering a therapy in evolution. *Circ Heart Fail*. 2008;1(3):200-205. doi:10.1161/CIRCHEARTFAILURE.108.782599

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

3. Kanduri J, Axman R, Lu DY, Feldman DN, Kim LK. Mechanical Circulatory Support: When and How to Use It. *Curr Treat Options Cardiovasc Med*. 2023;25(5):111-126. doi:10.1007/s11936-023-00980-x
4. Saeed D, Feldman D, Banayosy A El, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. *The Journal of Heart and Lung Transplantation*. 2023;42(7):e1-e222. doi:10.1016/j.healun.2022.12.004
5. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the Use of Mechanical Circulatory Support: Device Strategies and Patient Selection. *Circulation*. 2012;126(22):2648-2667. doi:10.1161/CIR.0b013e3182769a54
6. Singh TP, Hsich E, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation. *Journal of Heart and Lung Transplantation*. 2025;44(12):1857-1873. doi:10.1016/j.healun.2025.04.014
7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol*. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
8. Guglin M, Zucker MJ, Borlaug BA, et al. Evaluation for Heart Transplantation and LVAD Implantation: JACC Council Perspectives. *J Am Coll Cardiol*. 2020;75(12):1471-1487. doi:10.1016/j.jacc.2020.01.034
9. Bonow RO, Douglas PS, Buxton AE, et al. ACCF/AHA Methodology for the Development of Quality Measures for Cardiovascular Technology. *J Am Coll Cardiol*. 2011;58(14):1517-1538. doi:10.1016/j.jacc.2011.07.007
10. Fitch Kathryn, Bernstein SJ, Aguilar MD, et al. *The RAND/UCLA Appropriateness Method User's Manual*. RAND.; 2001. Accessed October 8, 2024. https://www.rand.org/pubs/monograph_reports/MR1269.html
11. Hendel RC, Patel MR, Allen JM, et al. Appropriate Use of Cardiovascular Technology: 2013 ACCF appropriate use criteria methodology update. *J Am Coll Cardiol*. 2013;61(12):1305-1317. doi:10.1016/j.jacc.2013.01.025
12. Patel MR, Spertus JA, Brindis RG, et al. ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging. *J Am Coll Cardiol*. 2005;46(8):1606-1613. doi:10.1016/j.jacc.2005.08.030

Disclaimer

Maryland Physicians Care medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the

EVH_CG_2709.MPC Mechanical Circulatory Support (Ventricular Assist Device) – Percutaneous and Permanent

Policy Number: EVH_CG_2709.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Maryland Physicians Care and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Maryland Physicians Care reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Maryland Physicians Care. Any sale, copying, or dissemination of said policies is prohibited.